[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) reported insider sales by Chief Executive Officer and Director Neil Kumar under a Rule 10b5-1 plan. The filing shows multiple market sales on 10/08/2025 and 10/09/2025, totaling 223,090 shares disposed at weighted-average prices in the mid-$54 range. Shares sold were held indirectly through two trusts for which the reporting person is a co-trustee; the report disclaims beneficial ownership except for any pecuniary interest. The transactions were reported on a Form 4 and signed by an attorney-in-fact on 10/10/2025.

Positive

• Sales executed under a Rule 10b5-1 plan, indicating pre-arranged transactions (plan adoption date 03/31/2025).
• Full disclosure on Form 4 with specific sale amounts and weighted-average prices, supporting regulatory transparency.

Negative

• Insider disposed of 223,090 shares, a material block of stock sold across 10/08/2025–10/09/2025.
• Sells reduce indirect trust holdings reported for the CEO (post-transaction indirect balances reported in the filing).

Insights

Corporate Governance Analyst

TL;DR: CEO sold 223,090 shares under a pre-established 10b5-1 plan; sales were from trust holdings.

The sales were executed under a Rule 10b5-1 plan adopted on 03/31/2025, which provides an affirmative defense to insider trading claims when conditions are met. The filing lists weighted-average sale prices in the ranges stated and shows proceeds were generated across 10/08/2025–10/09/2025.

Key dependencies include continued adherence to the plan's terms and that the reporting person disclaims direct beneficial ownership except for any pecuniary interest. Monitor subsequent Form 4 filings for additional plan activity or changes in beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		S(1)		8,706	D	$54.3882(2)	4,669,741	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	10/08/2025		S(1)		11,294	D	$55.0886(4)	4,658,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	10/09/2025		S(1)		20,000	D	$54.8023(5)	4,638,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	10/08/2025		S(1)		8,705	D	$54.3883(2)	866,981	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	10/08/2025		S(1)		11,295	D	$55.0886(4)	855,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	10/09/2025		S(1)		20,000	D	$54.8023(5)	835,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								223,090	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $53.82 to $54.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $54.82 to $55.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $54.49 to $55.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BridgeBio (BBIO) insider Neil Kumar sell?

The filing reports 223,090 shares sold across transactions on 10/08/2025 and 10/09/2025 at weighted-average prices in the mid-$54 range.

Were the sales part of a prearranged plan for BBIO?

Yes. The sales were effected pursuant to a Rule 10b5-1 sales plan adopted on 03/31/2025.

How did the reporting person hold the shares sold?

The shares were held indirectly through the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, of which the reporting person is a co-trustee.

When was the Form 4 filed and signed?

The transactions list earliest dates of 10/08/2025 and 10/09/2025, and the Form was signed by an attorney-in-fact on 10/10/2025.

Does the filing claim direct beneficial ownership by Neil Kumar?

The reporting person disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest, per the filing.